Acadia Pharmaceuticals Inc. has appointed Carl Segerstrom as Chief People Officer, effective July 6, to lead its global people and culture strategy. Segerstrom joins the executive leadership team to support the company's next phase of growth as a neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He brings more than 25 years of experience in global human resources leadership across the biopharmaceutical industry.

Catherine Owen Adams, Chief Executive Officer of Acadia, highlighted Segerstrom's track record of building high-performing organizations and shaping culture. She stated his experience driving transformation in complex, science-driven organizations will be instrumental as the company scales and advances its mission for patients.

Segerstrom most recently served as Senior Vice President, Human Resources at Merck’s Human Health Division. In this role, he supported a $50+ billion global business spanning 80 countries. His career at Merck included positions such as Chief Talent Officer, where he was responsible for global talent strategy, executive succession planning, leadership development, and workforce transformation.

Earlier in his career, Segerstrom held human resources leadership roles at Pharmacia, Schering-Plough, and Pfizer across multiple international markets. His expertise includes organizational transformation, talent strategy, large-scale workforce capability shifts, digital and AI-enabled initiatives, and global operating model redesign. He has also led talent acquisition organizations hiring more than 10,000 employees annually.

Carl Segerstrom's Career Highlights

Segerstrom holds a Master’s degree in Human Resources Management from Uppsala University in Sweden. He has completed executive development programs at Harvard Business School and the University of Chicago Booth School of Business.

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on ACADIA Pharmaceuticals, raising the price target to $30 from $29. The adjustment reflects an updated outlook on the NASDAQ-listed stock.

Rating and Price Target Details

The revised price target of $30 represents an increase from the previous target of $29. The Buy rating was maintained, indicating continued confidence in the company's performance.